UNSPSC 51142027: Flupirtine

This classification denotes an analgesic agent with the molecular formula C15H17FN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MOH3ET196H, chemically known as carbamic acid, (2-amino-6-(((4-fluorophenyl)methyl)amino)-3-pyridinyl)-, ethyl ester but generally known as flupirtine, which bears US NIH Compound Identifier 53276. European Medicines Agency schedules Flupirtine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07732MIG.

UNSPSC 51142027 Flupirtine is a Commodity code that nominally designates a specific analgesic pharmaceutical, yet the recent state and local activity tagged under it shows little direct procurement of flupirtine itself. Instead, the code appears in solicitations for broader pharmaceutical supply, naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals. State and local buyers using this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities across multiple states including Oregon). The scope of work reflects supply-chain and systems contracting rather than procurement of flupirtine as a discrete product — vendors are expected to manage wholesaler relationships, comply with Drug Supply Chain Security Act requirements, maintain cGMP certification, submit detailed product data via EDI, and in some cases negotiate direct contracts with state agencies outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent opportunities span Florida, Texas, and Minnesota-led multistate cooperative activity. Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs before a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with products required in the marketplace by May 15, 2026 and contract effectiveness July 1, 2026. Vendors must work through authorized wholesalers, maintain substantial insurance coverage including commercial general liability of $5,000,000 per occurrence, and accept a 3 percent administrative fee.